Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Mannkind ($MNKD) officials signaled that FDA approval of its inhaled diabetes Afrezza Inhalation Powder is likely at the company's May 22 shareholder meeting.
The company played patient testimony in support of Afrezza from the combination product's April 1 advisory committee hearing in which it voted in favor of the drug 13-1 for the treatment of Type 1 diabetes and 14-0 for the treatment of Type 2 diabetes.
"We are done with CRLs [complete response letters]. We are certainly not expecting that. We just had a very good conference call last week with the agency, and we are confident that we are well on our way," COO Hakan Edstrom told investors.
http://www.fiercedrugdelivery.com/s...inhaled-insulin-drug-around-corner/2014-05-28
Not for me thanks...🙄
The company played patient testimony in support of Afrezza from the combination product's April 1 advisory committee hearing in which it voted in favor of the drug 13-1 for the treatment of Type 1 diabetes and 14-0 for the treatment of Type 2 diabetes.
"We are done with CRLs [complete response letters]. We are certainly not expecting that. We just had a very good conference call last week with the agency, and we are confident that we are well on our way," COO Hakan Edstrom told investors.
http://www.fiercedrugdelivery.com/s...inhaled-insulin-drug-around-corner/2014-05-28
Not for me thanks...🙄
